1. S196: ROPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES. (23rd June 2022) Authors: Gisslinger, H.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Dulicek, P.; Illes, A.; Pylypenko, H.; Sivcheva, L.; Mayer, J.; Yablokova, V.; Empson, V.; Krejcy, K.; Hasselbalch, H.; Kralovics, R.; Kiladjian, J.-J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Issue 6 (November 2016) Authors: Barbui, T.; Thiele, J.; Gisslinger, H.; Finazzi, G.; Vannucchi, A.M.; Tefferi, A. Journal: Blood reviews Issue: Volume 30:Issue 6(2016:Nov.) Page Start: 453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Update on PEGINVERA and PROUD-PV studies. (May 2016) Authors: Gisslinger, H. Journal: Leukemia research Issue: Volume 44(2016:May)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗